Evidence map›Paper›PMID 42185779›Full record

SynthesisThe journal of headache and pain2026

Over 600 million people aged 18-65 will have headache tomorrow: global 1-day prevalence and recall bias from a meta-analysis of individual participant data (N = 38,512) from the general populations of 15 countries.

Andreas Kattem Husøy, Shengyuan Yu, Ruozhuo Liu, Akbar A Herekar, Bilal Ahmed, Arif D Herekar, Callixte Kuate Tegueu, Anastase Dzudie Tamdja, Annick Mélanie Magnerou, Najib Kissani and 31 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Andreas Kattem HusøyNorHead, Department of Neuromedicine and Movement Science, NTNU, Norwegian University of Science and Technology, Edvard Griegs gate, Trondheim, Norway. ahusoy@gmail.com.
Shengyuan YuDepartment of Neurology, Chinese PLA General Hospital, Beijing, China.
Ruozhuo LiuDepartment of Neurology, Chinese PLA General Hospital, Beijing, China.
Akbar A HerekarHeadache Research Foundation of Pakistan, Karachi, Pakistan.
Bilal AhmedHeadache Research Foundation of Pakistan, Karachi, Pakistan.
Arif D HerekarHeadache Research Foundation of Pakistan, Karachi, Pakistan.
Callixte Kuate TegueuDepartment of Neurology, Douala Laquintinie Hospital, Douala, Cameroon.
Anastase Dzudie TamdjaFaculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.
Annick Mélanie MagnerouDepartment of Neurology, Douala Laquintinie Hospital, Douala, Cameroon.
Najib KissaniLaboratory of Clinical and Experimental Neuroscience, Faculty of Medicine, Cadi Ayyad University, Marrakesh, Morocco.
Latifa AdarmouchCommunity Medicine and Public Health Department, Bioscience and Health Research Laboratory, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco.
Thierry AdoukonouDepartment of Neurology, University of Parakou, Parakou, Benin.
Mendinatou AgbetouDepartment of Neurology, University of Parakou, Parakou, Benin.
Oyéné KossiDepartment of Neurology, University of Parakou, Parakou, Benin.
Mehila ZebenigusDepartment of Neurology, School of Medicine, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia.
Redda Tekle-HaimanotDepartment of Internal Medicine, School of Medicine, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia.
Dawit K WorkuPulmonary Disease and Critical Care Medicine, Henry Ford Providence Southfield Hospital, Michigan State University College of Human Medicine, Southfield, MI, USA.
Girish N RaoCentre for Public Health, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
Girish B KulkarniDepartment of Clinical Neurosciences, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
Gopalkrishna GururajCentre for Public Health, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
Mohammed Al JumahKing Abdullah International Medical Research Centre, Riyadh, Saudi Arabia.
Ali M Al KhathaamiKing Abdullah International Medical Research Centre, Riyadh, Saudi Arabia.
Suliman KojanKing Abdullah International Medical Research Centre, Riyadh, Saudi Arabia.
Guiovanna QuispeNeurology Service, Hospital Luis Negreiros Vega, Callao, Peru.
Carlos Palomino-DiazNeurology Service, Hospital Luis Negreiros Vega, Callao, Peru.
Youssoufa MaigaDepartment of Neurology, Gabriel Touré Teaching Hospital, Bamako, Mali.
Robert P CowanDepartment of Neurology and Neurosciences, Stanford University School of Medicine, Stanford, CA, USA.
Mattias LindeNorHead, Department of Neuromedicine and Movement Science, NTNU, Norwegian University of Science and Technology, Edvard Griegs gate, Trondheim, Norway.
Ajay RisalDepartment of Psychiatry, Kathmandu University School of Medical Science, Katmandu, Nepal.
Debashish ChowdhuryGB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.
Krishnan AnandAll India Institute of Medical Sciences, New Delhi, India.
Ashish DuggalDepartment of Neurology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr RML Hospital, New Delhi, India.
Otgonbayar LuvsannorovDepartment of Neurology, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
Dorjkhand BaldorjDepartment of Neurology, Buyant Onoshlogoo Clinic, Ulaanbaatar, Mongolia.
Selenge EnkhtuyaReflex Neurology Hospital, Ulaanbaatar, Mongolia.
Ilya AyzenbergDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Zaza KatsaravaCentre of Neurology, Geriatric Medicine and Early Rehabilitation, Evangelical Hospital, Unna, Germany.
Gretchen L BirbeckNeurology Research Office, University Teaching Hospitals, Lusaka, Zambia.
Daiva RastenytėLithuanian University of Health Sciences, Kaunas, Lithuania.
Lars Jacob StovnerNorHead, Department of Neuromedicine and Movement Science, NTNU, Norwegian University of Science and Technology, Edvard Griegs gate, Trondheim, Norway.
Timothy J SteinerNorHead, Department of Neuromedicine and Movement Science, NTNU, Norwegian University of Science and Technology, Edvard Griegs gate, Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur recent estimate of the global 1-year prevalence of headache among those aged 18-65 years was 65%: considerably higher than previous estimates, but based solely on high-quality epidemiological data derived from a large population-based sample. Here we present complementary estimates of 1-day prevalence.

methodsWe performed a meta-analysis of individual participant data from cross-sectional surveys among population-representative samples (age range 18-65 years) from 15 countries and all world regions. All used the Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation (HARDSHIP) questionnaire, including the question "did you have a headache yesterday?", from which 1-day prevalence was determined. An algorithmic process applying modified ICHD criteria yielded separate estimates for migraine, tension-type headache (TTH) and probable medication-overuse headache (pMOH: the association of headache on ≥ 15 days/month and medication overuse). We analysed associations with age, gender and country-income level, and adjusted prevalence estimates for these factors. We calculated predicted 1-day prevalence from 1-year prevalence and reported headache frequency.

resultsAmong the 38,512 participants, females (53.4%) and participants from low- (17.1%) or lower-middle-income countries (64.6%) were overrepresented, but age distribution fairly matched that of the world. Overall, 13.7% (95% CI: 13.3-14.0) reported headache yesterday, females (17.1% [16.6-17.6]) more than males (9.7% [9.3-10.2]). Migraine was the most common headache type yesterday (6.0% [5.8-6.3]), followed by TTH (4.1% [3.9-4.3]) and pMOH (2.3% [2.2-2.5]). One-day headache prevalence was higher in low/lower-middle-income countries (13.9% [13.6-14.3]) than in high/upper-middle-income countries (12.4% [11.6-13.2]). Predicted 1-day prevalence (10.9% [10.7-11.1]) was considerably lower than observed 1-day prevalence (13.7% [13.3-14.0]), although not among those with pMOH (3.1% [3.0-3.3] versus 2.3% [2.2-2.5]). Adjusted for age, gender and country-income level, global 1-day prevalence estimates were 13.1% (12.8-13.5) for any headache, 5.7% (5.5-5.9) for migraine, 3.9% (3.7-4.1) for TTH and 2.4% (2.3-2.6) for pMOH, with 1.0% undiagnosed.

conclusionAssuming yesterday was no different from any other day, an estimated 13.1% (N = 641,900,000) of the world's population aged 18-65 years will have headache tomorrow; almost half will be migraine. People with migraine or TTH underestimate the frequency of headache episodes. Since headache-attributed burden is usually estimated from recalled frequency over 1-12 months, this also may be underestimated.

Indexed as

HeadacheAdolescentAdultAgedCross-Sectional StudiesFemaleGlobal HealthHumansMaleMiddle AgedPrevalenceYoung Adult1-day prevalenceDefinite migraineDefinite tension type headacheGlobal Burden of Disease (GBD)Global Campaign against HeadacheHARDSHIP questionnaireIndividual participant dataMedication-overuse headacheMeta-analysisMigrainePopulation-based studyProbable migraineProbable tension type headacheTension type headache

Identifiers

PMID42185779
PMCPMC13217788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.